BNP and NTproBNP Global Market Report 2024

The bnp and ntprobnp market has grown rapidly in recent years. It will grow from $1.77 billion in 2023 to $2 billion in 2024 at a compound annual growth rate (CAGR) of 13.2%. The expansion witnessed in the historic period can be attributed to several factors, including the aging population demographic, the clinical significance of these tests in diagnosing heart failure, notable advancements in the field of cardiovascular medicine, and an increasing emphasis on preventive healthcare measures.

The bnp and ntprobnp market is expected to see rapid growth in the next few years. It will grow to $3.15 billion in 2028 at a compound annual growth rate (CAGR) of 12.1%. Anticipated growth in the forecast period can be traced back to several key drivers, such as the escalating burden of cardiovascular diseases, the integration of these tests into point-of-care settings, the broadening spectrum of applications across various medical conditions, the implementation of personalized medicine strategies, and the increasing reliance on telemedicine and remote monitoring in healthcare.

The increasing prevalence of cardiovascular diseases is set to drive the growth of the BNP and NTproBNP market moving ahead. These diseases affect the heart and blood vessels, encompassing conditions such as peripheral arterial disease, cerebrovascular disease, and coronary heart disease. BNP and NTproBNP tests play a crucial role in heart health monitoring, aiding in preemptive measures and reducing mortality risks by identifying factors contributing to cardiovascular diseases. For example, according to the UK's Office for National Statistics, deaths attributed to heart attacks rose from 19,440 in 2020 to 20,061 in 2021. This surge in cardiovascular diseases is a catalyst for the BNP and NTproBNP markets' growth.

The expanding geriatric demographic is anticipated to be a driving force for the BNP and NTproBNP market's expansion. This segment, comprising individuals aged 65 or older, finds critical assistance from BNP and NTproBNP tests in diagnosing and managing heart failure. These biomarkers provide valuable insights into cardiac function, aiding in tailored treatment strategies for elderly individuals. The World Health Organization reports that by 2030, one in six individuals globally will be 60 or older, projected to reach 2.1 billion elderly individuals by 2050. Hence, the burgeoning geriatric population propels the growth of the BNP and NTproBNP market.

Innovation in product development emerges as a significant trend driving the BNP and NTproBNP markets. Leading companies in these markets prioritize introducing novel products to maintain their market positions. For instance, in May 2023, Randox Laboratories unveiled a BNP1-32 diagnostic test for heart failure diagnosis. This automated test measures BNP levels with high sensitivity and specificity, integrating with third-party controls and software for effective QC data monitoring. This control ensures accurate and reliable BNP testing.

Prominent companies in the BNP and NTproBNP market are intensifying their focus on rapid screening bioassays to gain a competitive edge. Rapid screening bioassays efficiently assess substance presence or concentration by measuring effects on living cells or organisms, aiding in swift and reliable attribute identification or condition categorization. Mindray Medical International Limited, in October 2023, introduced two new assays - high-sensitivity troponin I (hs-cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). These assays bolster Mindray's ability to screen, risk-stratify, diagnose rapidly, and monitor therapy for cardiovascular diseases, enhancing their portfolio for efficient disease management. Mindray's collaboration with HyTest further strengthens its immunoassay platforms, integrating advanced research and antibodies for cardiac biomarkers.

In July 2021, Beckman Coulter, a leading US-based clinical diagnostics provider, finalized definitive agreements with Quidel Corporation to secure full rights for manufacturing, distributing, and marketing BNP assays specifically tailored for Beckman Coulter analyzers. As part of this arrangement, Quidel remains responsible for manufacturing and supplying specific components crucial to the assay for Beckman Coulter's use. Meanwhile, Beckman Coulter exclusively handles the production and commercialization of the BNP assay to its customer base, marketing it under the brand name Access BNP. Quidel Corporation, also based in the US, specializes in manufacturing diagnostic healthcare products and operates within the BNP and NTproBNP market segments.

Major companies operating in the bnp and ntprobnp market report are Abbott Laboratories,Gentian Diagnostics ASA,Siemens AG,PerkinElmer Inc.,Biomerieux SA,Quidel Corporation,Bio-Rad Laboratories Inc.,F Hoffman La Roche Ltd.,CTK Biotech Inc.,RayBiotech Life Inc.,BHR Pharmaceuticals Ltd.,Getein Biotech Inc.,VACURE Biotechnology Co. Ltd.,Bio-Techne Co.,Xiamen Biotime Biotechnology Co. Ltd.,Scripps Laboratories Inc.,Danaher Corporation,Beckman Coulter Inc.,Thermo Fisher Scientific Inc.,Randox Laboratories Ltd.,LSI Medience Corporation,Shionogi & Co. Ltd.,Radiometer Medical ApS,Ortho Clinical Diagnostics,Tosoh Corporation,Aidian Oy,Shenzhen Mindray Bio-Medical Electronics Co. Ltd.,Becton Dickinson and Company,Acon Laboratories Inc.,Response Biomedical Corp.,Nanomix Inc.,Cepheid Inc.,Alere Inc.

Asia-Pacific was the largest region in the BNP and NTproBNP market in 2023. North America is expected to be the fastest-growing region in the global BNP and NTproBNP market report during the forecast period. The regions covered in the bnp and ntprobnp market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bnp and ntprobnp market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

These tests primarily involve measuring the quantities of BNP (brain natriuretic peptide) and NT-proBNP (N-terminal pro-B-type natriuretic peptide) in the bloodstream. The BNP test specifically targets BNP levels, aiding in the detection of heart failure and other cardiac conditions. Testing locations encompass both point-of-care and laboratory settings, facilitating diagnostics for myocardial infarction, congestive heart failure, acute coronary syndrome (ACS), and other related ailments.

The BNP and NTproBNP market research report provides BNP and NTproBNP market statistics, including the BNP and NTproBNP industry global market size, regional shares, competitors with a BNP and NTproBNP market share, detailed BNP and NTproBNP market segments, market trends, and opportunities, and any further data you may need to thrive in the BNP and NTproBNP industry. This BNP and NTproBNP market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The BNP and NTproBNP market includes revenues earned by companies by providing diagnostic and heart disease detection services using BNP (B-type natriuretic peptide) or NT-proBNP (N-terminal Pro-brain Natriuretic Peptide) as biomarkers, BNP and NTproBNP assays. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.